This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abou-Elella, A. A. Articles by Armitage, J. O. Search for Related Content PubMed PubMed Citation Articles by Abou-Elella, A. A. Articles by Armitage, J. O. Social Bookmarking                            What's this?

Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group

From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE.

Address reprint requests to Dennis D. Weisenburger, MD, Department of Pathology and Microbiology, 983135 Nebraska Medical Center, Omaha, NE 68198-3135; email dweisenb{at}unmc.edu

PURPOSE: To investigate whether primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathologic entity with a more aggressive course than other diffuse large B-cell lymphomas (DLBL).

MATERIALS AND METHODS: All patients with CD20-positive DLBL who presented with a mediastinal mass measuring at least 5.0 cm and were treated with curative intent were identified. A control group of 352 patients with nonmediastinal DLBL was selected for comparison.

RESULTS: The 43 patients with PMLBL had a male to female ratio of 20:23 and a median age of 42 years. Stage I/II disease was present in 58% of the patients, with only 9% having bone marrow involvement. A complete remission was achieved in 63% of the patients, and the 5-year overall and failure-free survivals were 46% and 38%, respectively. Among the clinical variables, an elevated serum lactate dehydrogenase level, a low performance score, more than one extranodal site, and an intermediate or high International Prognostic Index score were predictive of poor survival. When compared with the DLBL group, a younger median age was the only clinical feature that was significantly different in the PMLBL group.

CONCLUSION: The clinical features of PMLBL do not appear to be significantly different from those of nonmediastinal DLBL. Although the younger age of onset, slight female predominance, mediastinal location, and size of the mass may justify the recognition of PMLBL as a clinical syndrome, additional evidence is needed to define it as a distinct disease entity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. L. Zinzani, M. Martelli, V. Poletti, U. Vitolo, P. G. Gobbi, T. Chisesi, G. Barosi, A. J.M. Ferreri, M. Marchetti, N. Pimpinelli, et al. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, September 1, 2008; 93(9): 1364 - 1371. [Abstract] [Full Text] [PDF]

				L. N. Shulman, R. A. Hitt, and J. A. Ferry Case 4-2008 -- A 33-Year-Old Pregnant Woman with Swelling of the Left Breast and Shortness of Breath N. Engl. J. Med., January 31, 2008; 358(5): 513 - 523. [Full Text] [PDF]

				P. W.M. Johnson and A. J. Davies Primary Mediastinal B-Cell Lymphoma Hematology, January 1, 2008; 2008(1): 349 - 358. [Abstract] [Full Text] [PDF]

				R. A. Roberts, G. Wright, A. R. Rosenwald, M. A. Jaramillo, T. M. Grogan, T. P. Miller, Y. Frutiger, W. C. Chan, R. D. Gascoyne, G. Ott, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival Blood, July 1, 2006; 108(1): 311 - 318. [Abstract] [Full Text] [PDF]

				A. Rosenwald, G. Wright, K. Leroy, X. Yu, P. Gaulard, R. D. Gascoyne, W. C. Chan, T. Zhao, C. Haioun, T. C. Greiner, et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma J. Exp. Med., September 15, 2003; 198(6): 851 - 862. [Abstract] [Full Text] [PDF]

				K. Seidemann, M. Tiemann, I. Lauterbach, G. Mann, I. Simonitsch, K. Stankewitz, M. Schrappe, M. Zimmermann, C. Niemeyer, R. Parwaresch, et al. Primary Mediastinal Large B-Cell Lymphoma With Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-Munster Group J. Clin. Oncol., May 1, 2003; 21(9): 1782 - 1789. [Abstract] [Full Text] [PDF]

				S. A. Pileri, G. Gaidano, P. L. Zinzani, B. Falini, P. Gaulard, E. Zucca, F. Pieri, E. Berra, E. Sabattini, S. Ascani, et al. Primary Mediastinal B-Cell Lymphoma: High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB.1, and PU.1 in the Absence of Immunoglobulins Am. J. Pathol., January 1, 2003; 162(1): 243 - 253. [Abstract] [Full Text] [PDF]

				K. van Besien, M. Kelta, and P. Bahaguna Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864. [Abstract] [Full Text] [PDF]